JPWO2020102422A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020102422A5
JPWO2020102422A5 JP2021525789A JP2021525789A JPWO2020102422A5 JP WO2020102422 A5 JPWO2020102422 A5 JP WO2020102422A5 JP 2021525789 A JP2021525789 A JP 2021525789A JP 2021525789 A JP2021525789 A JP 2021525789A JP WO2020102422 A5 JPWO2020102422 A5 JP WO2020102422A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable domain
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021525789A
Other languages
Japanese (ja)
Other versions
JP2022507295A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061278 external-priority patent/WO2020102422A1/en
Publication of JP2022507295A publication Critical patent/JP2022507295A/en
Publication of JPWO2020102422A5 publication Critical patent/JPWO2020102422A5/ja
Withdrawn legal-status Critical Current

Links

Claims (18)

ヒトＳＩＲＰαに特異的に結合するモノクローナル抗体又はその抗原結合断片であって、前記モノクローナル抗体又はその抗原結合断片が、
ｉ．配列番号１、配列番号２、配列番号３；
ｉｉ．配列番号４、配列番号５、配列番号６；
ｉｉｉ．配列番号７、配列番号８、配列番号９；
ｉｖ．配列番号１１、配列番号１１、配列番号１２；
ｖ．配列番号１３、配列番号１４、配列番号１５；
ｖｉ．配列番号１６、配列番号１７、配列番号１８；
ｖｉｉ．配列番号１９、配列番号２０、配列番号２１；
ｖｉｉｉ．配列番号２２、配列番号２３、配列番号２４；
ｉｘ．配列番号２５、配列番号２６、配列番号２７；
ｘ．配列番号２８、配列番号２９、配列番号３０；
ｘｉ．配列番号１０、配列番号３１、配列番号１２；
ｘｉｉ．配列番号１０、配列番号３１、配列番号３２；及び
ｘｉｉｉ．配列番号２５、配列番号２６、配列番号２７、
からなる群から選択される３つの軽鎖相補性決定領域（ＬＣＤＲ１、ＬＣＤＲ２、ＬＣＤＲ３）と、
ｉ．配列番号３３、配列番号３４、配列番号３５；
ｉｉ．配列番号３６、配列番号３７、配列番号３８；
ｉｉｉ．配列番号３９、配列番号４０、配列番号４１；
ｉｖ．配列番号４２、配列番号４３、配列番号４４；
ｖ．配列番号４５、配列番号４６、配列番号４７；
ｖｉ．配列番号４８、配列番号４９、配列番号５０；
ｖｉｉ．配列番号５１、配列番号５２、配列番号５３；
ｖｉｉｉ．配列番号５４、配列番号５５、配列番号５６；
ｉｘ．配列番号５７、配列番号５８、配列番号５９；
ｘ．配列番号６０、配列番号６１、配列番号６２；及び
ｘｉ．配列番号５７、配列番号５８、配列番号６３；
からなる群から選択される３つの重鎖相補性決定領域（ＨＣＤＲ１、ＨＣＤＲ２、ＨＣＤＲ３）と、を含む、モノクローナル抗体又はその抗原結合断片。 A monoclonal antibody or antigen-binding fragment thereof that specifically binds to human SIRPα, wherein the monoclonal antibody or antigen-binding fragment thereof comprises
i. SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3;
ii. SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6;
iii. SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9;
iv. SEQ ID NO: 11, SEQ ID NO: 11, SEQ ID NO: 12;
v. SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15;
vi. SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18;
vii. SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21;
viii. SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24;
ix. SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27;
x. SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30;
xi. SEQ ID NO: 10, SEQ ID NO: 31, SEQ ID NO: 12;
xii. SEQ ID NO: 10, SEQ ID NO: 31, SEQ ID NO: 32; and
xiii. SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27,
three light chain complementarity determining regions (LCDR1, LCDR2, LCDR3) selected from the group consisting of
i. SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35;
ii. SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38;
iii. SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41;
iv. SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44;
v. SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47;
vi. SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50;
vii. SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53;
viii. SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56;
ix. SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59;
x. SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62; and
xi. SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 63;
A monoclonal antibody or antigen-binding fragment thereof, comprising three heavy chain complementarity determining regions (HCDR1, HCDR2, HCDR3) selected from the group consisting of: 前記モノクローナル抗体又はその抗原結合断片がキメラであるか、又はヒト化されている抗体である、請求項１に記載のモノクローナル抗体又はその抗原結合断片。 2. The monoclonal antibody or antigen-binding fragment thereof of claim 1, wherein said monoclonal antibody or antigen-binding fragment thereof is a chimeric or humanized antibody . ｉ． 配列番号８１のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号６４を含む軽鎖可変ドメイン；
ｉｉ． 配列番号８２のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号６５を含む軽鎖可変ドメイン；
ｉｉｉ． 配列番号８３のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号６６を含む軽鎖可変ドメイン；
ｉｖ． 配列番号８４のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号６７を含む軽鎖可変ドメイン；
ｖ． 配列番号８５のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号６８を含む軽鎖可変ドメイン；
ｖｉ． 配列番号８６のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号６９を含む軽鎖可変ドメイン；
ｖｉｉ． 配列番号８７のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７０を含む軽鎖可変ドメイン；
ｖｉｉｉ． 配列番号８８のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７１を含む軽鎖可変ドメイン；
ｉｘ． 配列番号８９のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７２を含む軽鎖可変ドメイン；
ｘ． 配列番号９０のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７３を含む軽鎖可変ドメイン；
ｘｉ． 配列番号９１のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７４を含む軽鎖可変ドメイン；
ｘｉｉ． 配列番号９１のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７５を含む軽鎖可変ドメイン；
ｘｉｉｉ． 配列番号９１のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７６を含む軽鎖可変ドメイン；
ｘｉｖ． 配列番号９２のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７４を含む軽鎖可変ドメイン；
ｘｖ． 配列番号９２のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７５を含む軽鎖可変ドメイン；
ｘｖｉ． 配列番号９２のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７６を含む軽鎖可変ドメイン；
ｘｖｉｉ． 配列番号９３のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７４を含む軽鎖可変ドメイン；
ｘｖｉｉｉ． 配列番号９３のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７５を含む軽鎖可変ドメイン；
ｘｉｘ． 配列番号９３のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７６を含む軽鎖可変ドメイン；
ｘｘ． 配列番号９４のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７４を含む軽鎖可変ドメイン；
ｘｘｉ． 配列番号９４のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７５を含む軽鎖可変ドメイン；
ｘｘｉｉ． 配列番号９４のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７６を含む軽鎖可変ドメイン；
ｘｘｉｉｉ． 配列番号８４のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７７を含む軽鎖可変ドメイン；
ｘｘｉｖ． 配列番号９５のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７８を含む軽鎖可変ドメイン；
ｘｘｖ． 配列番号９５のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７９を含む軽鎖可変ドメイン；
ｘｘｖｉ． 配列番号９５のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号８０を含む軽鎖可変ドメイン；
ｘｘｖｉｉ． 配列番号９６のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７８を含む軽鎖可変ドメイン；
ｘｘｖｉｉｉ． 配列番号９６のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７９を含む軽鎖可変ドメイン；
ｘｘｉｘ． 配列番号９６のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号８０を含む軽鎖可変ドメイン；
ｘｘｘ． 配列番号９７のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７８を含む軽鎖可変ドメイン；
ｘｘｘｉ． 配列番号９７のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７９を含む軽鎖可変ドメイン；
ｘｘｘｉｉ． 配列番号９７のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号８０を含む軽鎖可変ドメイン；並びに
ｘｘｘｉｉｉ． 配列番号８９のアミノ酸配列を含む重鎖可変ドメイン及びアミノ酸配列配列番号７２を含む軽鎖可変ドメイン
からなる群から選択される、重鎖可変ドメイン（Ｖ Ｈ ）及び軽鎖可変ドメイン（Ｖ Ｌ ）を含む、請求項１に記載のモノクローナル抗体又はその抗原結合断片。 i. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:81 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:64;
ii. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:82 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:65;
iii. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:83 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:66;
iv. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:84 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:67;
v. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:85 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:68;
vi. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:86 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:69;
vii. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:87 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:70;
viii. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:88 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:71;
ix. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:89 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:72;
x. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:90 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:73;
xi. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:91 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:74;
xii. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:91 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:75;
xiii. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:91 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:76;
xiv. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:92 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:74;
xv. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:92 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:75;
xvi. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:92 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:76;
xvii. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:93 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:74;
xviii. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:93 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:75;
xix. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:93 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:76;
xx. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:94 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:74;
xxi. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:94 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:75;
xxii. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:94 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:76;
xxiii. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:84 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:77;
xxiv. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:95 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:78;
xxv. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:95 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:79;
xxvi. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:95 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:80;
xxvii. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:96 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:78;
xxviii. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:96 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:79;
xxix. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:96 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:80;
xxx. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:97 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:78;
xxxi. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:97 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:79;
xxxii. a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:97 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:80; and xxxiii. a heavy chain variable domain (V H ) and a light chain variable domain (V L ) selected from the group consisting of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:89 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:72; 2. The monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising : ｉ． 配列番号１０９のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号９８を含む軽鎖；
ｉｉ． 配列番号１１０のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号９９を含む軽鎖；
ｉｉｉ． 配列番号１１１のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１００を含む軽鎖；
ｉｖ． 配列番号１１２のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０１を含む軽鎖；
ｖ． 配列番号１１２のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０２を含む軽鎖；
ｖｉ． 配列番号１１２のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０３を含む軽鎖；
ｖｉｉ． 配列番号１１３のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０１を含む軽鎖；
ｖｉｉｉ． 配列番号１１３のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０２を含む軽鎖；
ｉｘ． 配列番号１１３のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０３を含む軽鎖；
ｘ． 配列番号１１４のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０１を含む軽鎖；
ｘｉ． 配列番号１１４のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０２を含む軽鎖；
ｘｉｉ． 配列番号１１４のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０３を含む軽鎖；
ｘｉｉｉ． 配列番号１１５のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０１を含む軽鎖；
ｘｉｖ． 配列番号１１５のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０２を含む軽鎖；
ｘｖ． 配列番号１１５のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０３を含む軽鎖；
ｘｖｉ． 配列番号１１６のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０４を含む軽鎖；
ｘｖｉｉ． 配列番号１１７のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０５を含む軽鎖；
ｘｖｉｉｉ． 配列番号１１７のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０６を含む軽鎖；
ｘｉｘ． 配列番号１１７のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０７を含む軽鎖；
ｘｘ． 配列番号１１８のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０５を含む軽鎖；
ｘｘｉ． 配列番号１１８のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０６を含む軽鎖；
ｘｘｉｉ． 配列番号１１８のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０７を含む軽鎖；
ｘｘｉｉｉ． 配列番号１１９のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０５を含む軽鎖；
ｘｘｉｖ． 配列番号１１９のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０６を含む軽鎖；
ｘｘｖ． 配列番号１１９のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０７を含む軽鎖；並びに
ｘｘｖｉ． 配列番号１２０のアミノ酸配列を含む重鎖及びアミノ酸配列配列番号１０８を含む軽鎖
からなる群から選択される１つの重鎖及び１つの軽鎖を含む、請求項３に記載のモノクローナル抗体又はその抗原結合断片。 i. a heavy chain comprising the amino acid sequence of SEQ ID NO: 109 and a light chain comprising the amino acid sequence SEQ ID NO: 98;
ii. a heavy chain comprising the amino acid sequence of SEQ ID NO:110 and a light chain comprising the amino acid sequence SEQ ID NO:99;
iii. a heavy chain comprising the amino acid sequence of SEQ ID NO: 111 and a light chain comprising the amino acid sequence SEQ ID NO: 100;
iv. a heavy chain comprising the amino acid sequence of SEQ ID NO: 112 and a light chain comprising the amino acid sequence SEQ ID NO: 101;
v. a heavy chain comprising the amino acid sequence of SEQ ID NO: 112 and a light chain comprising the amino acid sequence SEQ ID NO: 102;
vi. a heavy chain comprising the amino acid sequence of SEQ ID NO: 112 and a light chain comprising the amino acid sequence SEQ ID NO: 103;
vii. a heavy chain comprising the amino acid sequence of SEQ ID NO: 113 and a light chain comprising the amino acid sequence SEQ ID NO: 101;
viii. a heavy chain comprising the amino acid sequence of SEQ ID NO: 113 and a light chain comprising the amino acid sequence SEQ ID NO: 102;
ix. a heavy chain comprising the amino acid sequence of SEQ ID NO: 113 and a light chain comprising the amino acid sequence SEQ ID NO: 103;
x. a heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a light chain comprising the amino acid sequence SEQ ID NO: 101;
xi. a heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a light chain comprising the amino acid sequence SEQ ID NO: 102;
xii. a heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a light chain comprising the amino acid sequence SEQ ID NO: 103;
xiii. a heavy chain comprising the amino acid sequence of SEQ ID NO: 115 and a light chain comprising the amino acid sequence SEQ ID NO: 101;
xiv. a heavy chain comprising the amino acid sequence of SEQ ID NO: 115 and a light chain comprising the amino acid sequence SEQ ID NO: 102;
xv. a heavy chain comprising the amino acid sequence of SEQ ID NO: 115 and a light chain comprising the amino acid sequence SEQ ID NO: 103;
xvi. a heavy chain comprising the amino acid sequence of SEQ ID NO: 116 and a light chain comprising the amino acid sequence SEQ ID NO: 104;
xvii. a heavy chain comprising the amino acid sequence of SEQ ID NO: 117 and a light chain comprising the amino acid sequence SEQ ID NO: 105;
xviii. a heavy chain comprising the amino acid sequence of SEQ ID NO: 117 and a light chain comprising the amino acid sequence SEQ ID NO: 106;
xix. a heavy chain comprising the amino acid sequence of SEQ ID NO: 117 and a light chain comprising the amino acid sequence SEQ ID NO: 107;
xx. a heavy chain comprising the amino acid sequence of SEQ ID NO: 118 and a light chain comprising the amino acid sequence SEQ ID NO: 105;
xxi. a heavy chain comprising the amino acid sequence of SEQ ID NO: 118 and a light chain comprising the amino acid sequence SEQ ID NO: 106;
xxii. a heavy chain comprising the amino acid sequence of SEQ ID NO: 118 and a light chain comprising the amino acid sequence SEQ ID NO: 107;
xxiii. a heavy chain comprising the amino acid sequence of SEQ ID NO: 119 and a light chain comprising the amino acid sequence SEQ ID NO: 105;
xxiv. a heavy chain comprising the amino acid sequence of SEQ ID NO: 119 and a light chain comprising the amino acid sequence SEQ ID NO: 106;
xxv. a heavy chain comprising the amino acid sequence of SEQ ID NO: 119 and a light chain comprising the amino acid sequence SEQ ID NO: 107; and xxvi. 4. The monoclonal antibody of claim 3 , comprising one heavy chain and one light chain selected from the group consisting of a heavy chain comprising the amino acid sequence of SEQ ID NO: 120 and a light chain comprising the amino acid sequence SEQ ID NO: 108, or Antigen-binding fragment. 前記モノクローナル抗体又はその抗原結合断片が、ＩｇＧ１、ＩｇＧ１－Ｎ２９７Ｑ、ＩｇＧ２、ＩｇＧ４、ＩｇＧ４ Ｓ２２８Ｐ、ＩｇＧ４ ＰＥ及びこれらの変異体からなる群から選択されるＩｇＧアイソタイプを含む、請求項３に記載のモノクローナル抗体又はその抗原結合断片。 4. The monoclonal antibody of claim 3 , wherein said monoclonal antibody or antigen-binding fragment thereof comprises an IgG isotype selected from the group consisting of IgG1, IgG1-N297Q, IgG2, IgG4, IgG4 S228P, IgG4 PE and variants thereof. or an antigen-binding fragment thereof. ヒトＳＩＲＰαに選択的に結合する、請求項１に記載のモノクローナル抗体又はその抗原結合断片。 2. The monoclonal antibody or antigen-binding fragment thereof according to claim 1 , which selectively binds to human SIRPα. ヒトＳＩＲＰα及びヒトＳＩＲＰγに結合する、請求項１に記載のモノクローナル抗体又はその抗原結合断片。 2. The monoclonal antibody or antigen-binding fragment thereof according to claim 1 , which binds to human SIRPα and human SIRPγ . 抗腫瘍活性を示す、請求項１に記載のモノクローナル抗体又はその抗原結合断片。 The monoclonal antibody or antigen-binding fragment thereof according to claim 1 , which exhibits antitumor activity. ヒト腫瘍細胞の食作用を増大させる、請求項１に記載のモノクローナル抗体又はその抗原結合断片。 2. The monoclonal antibody or antigen-binding fragment thereof of claim 1 , which increases phagocytosis of human tumor cells. 請求項１に記載のモノクローナル抗体又はその抗原結合断片と、薬学的若しくは生理学的に許容される担体、希釈剤、又は賦形剤と、を含む医薬組成物。A pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically or physiologically acceptable carrier, diluent, or excipient. 治療を必要とする対象において癌を治療するための請求項１０に記載の組成物であって、前記組成物が、癌を治療するために有効な量で前記対象に投与される、組成物。11. The composition of claim 10 for treating cancer in a subject in need thereof, wherein said composition is administered to said subject in an amount effective to treat cancer. 前記モノクローナル抗体又はその抗原結合断片が、化学療法剤又は治療用抗体と組み合わせて投与される、請求項１１に記載の癌治療用組成物。12. The composition for treating cancer according to claim 11, wherein said monoclonal antibody or antigen-binding fragment thereof is administered in combination with a chemotherapeutic agent or therapeutic antibody. 前記治療用抗体が、ＣＤ４７（分化抗原群４７）、ＣＤ７０（分化抗原群７０）、ＣＤ２００（ＯＸ－２膜糖タンパク質、分化抗原群２００）、ＣＤ１５４（分化抗原群１５４、ＣＤ４０Ｌ、ＣＤ４０リガンド、分化抗原群４０リガンド）、ＣＤ２２３（リンパ球活性化遺伝子３、ＬＡＧ３、分化抗原群２２３）、ＫＩＲ（キラー細胞免疫グロブリン様受容体）、ＧＩＴＲ（ＴＮＦＲＳＦ１８、グルココルチコイド誘導性ＴＮＦＲ関連タンパク質、活性化誘導性ＴＮＦＲファミリー受容体、ＡＩＴＲ、腫瘍壊死因子受容体スーパーファミリーメンバー１８）、ＣＤ２０（分化抗原群）、ＣＤ２８（分化抗原群２８）、ＣＤ４０（分化抗原群４０、Ｂｐ５０、ＣＤＷ４０、ＴＮＦＲＳＦ５、腫瘍壊死因子受容体スーパーファミリーメンバー５、ｐ５０）、ＣＤ８６（Ｂ７－２、分化抗原群８６）、ＣＤ１６０（分化抗原群１６０、ＢＹ５５、ＮＫ１、ＮＫ２８）、ＣＤ２５８（ＬＩＧＨＴ、分化抗原群２５８、腫瘍壊死因子リガンドスーパーファミリーメンバー１４、ＴＮＦＳＦ１４、ヘルペスウイルス侵入メディエータリガンド（ＨＶＥＭ－Ｌ）、ＣＤ２７０（ＨＶＥＭ、腫瘍壊死因子受容体スーパーファミリーメンバー１４、ヘルペスウイルス侵入メディエータ、分化抗原群２７０、ＬＩＧＨＴＲ、ＨＶＥＡ）、ＣＤ２７５（ＩＣＯＳＬ、ＩＣＯＳリガンド、誘導性Ｔ細胞共刺激因子リガンド、分化抗原群２７５）、ＣＤ２７６（Ｂ７－Ｈ３、Ｂ７ホモログ３、分化抗原群２７６）、ＯＸ４０Ｌ（ＯＸ４０リガンド）、Ｂ７－Ｈ４（Ｂ７ホモログ４、ＶＴＣＮ１、Ｖセットドメイン含有Ｔ細胞活性化インヒビター１）、ＧＩＴＲＬ（グルココルチコイド誘導性腫瘍壊死因子受容体リガンド、グルココルチコイド誘導性ＴＮＦＲリガンド）、４－１ＢＢＬ（４－１ＢＢリガンド）、ＣＤ３（分化抗原群３、Ｔ３Ｄ）、ＣＤ２５（ＩＬ２Ｒα、分化抗原群２５、インターロイキン－２受容体α鎖、ＩＬ－２受容体α鎖）、ＣＤ４８（分化抗原群４８、Ｂリンパ球活性化マーカー、ＢＬＡＳＴ－１、シグナル伝達リンパ球活性化分子２、ＳＬＡＭＦ２）、ＣＤ６６ａ（Ｃｅａｃａｍ－１、癌胎児性抗原関連細胞接着分子１、胆汁糖タンパク質、ＢＧＰ、ＢＧＰ１、ＢＧＰＩ、分化抗原群６６ａ）、ＣＤ８０（Ｂ７－１、分化抗原群８０）、ＣＤ９４（分化抗原群９４）、ＮＫＧ２Ａ（ナチュラルキラー群２Ａ、キラー細胞レクチン様受容体サブファミリーＤメンバー１、ＫＬＲＤ１）、ＣＤ９６（分化抗原群９６、ＴＡｃｔＩＬＥ、Ｔ細胞活性化増大後期発現）、ＣＤ１１２（ＰＶＲＬ２、ネクチン、ポリオウイルス受容体関連２、ヘルペスウイルス侵入メディエータＢ、ＨＶＥＢ、ネクチン－２、分化抗原群１１２）、ＣＤ１１５（ＣＳＦ１Ｒ、コロニー刺激因子１受容体、マクロファージコロニー刺激因子受容体、Ｍ－ＣＳＦＲ、分化抗原群１１５）、ＣＤ２０５（ＤＥＣ－２０５、ＬＹ７５、リンパ球抗原７５、分化抗原群２０５）、ＣＤ２２６（ＤＮＡＭ１、分化抗原群２２６、ＤＮＡＸアクセサリー分子－１、ＰＴＡ１、血小板及びＴ細胞活性化抗原１）、ＣＤ２４４（分化抗原群２４４、ナチュラルキラー細胞受容体２Ｂ４）、ＣＤ２６２（ＤＲ５、ＴｒａｉｌＲ２、ＴＲＡＩＬ－Ｒ２、腫瘍壊死因子受容体スーパーファミリーメンバー１０ｂ、ＴＮＦＲＳＦ１０Ｂ、分化抗原群２６２、ＫＩＬＬＥＲ、ＴＲＩＣＫ２、ＴＲＩＣＫＢ、ＺＴＮＦＲ９、ＴＲＩＣＫ２Ａ、ＴＲＩＣＫ２Ｂ）、ＣＤ２８４（Ｔｏｌｌ様受容体－４、ＴＬＲ４、分化抗原群２８４）、ＣＤ２８８（Ｔｏｌｌ様受容体－８、ＴＬＲ８、分化抗原群２８８）、白血病阻害因子（ＬＩＦ）、ＴＮＦＳＦ１５（腫瘍壊死因子スーパーファミリーメンバー１５、血管内皮増殖インヒビター、ＶＥＧＩ、ＴＬ１Ａ）、ＴＤＯ２（トリプトファン２，３－ジオキシゲナーゼ、ＴＰＨ２、ＴＲＰＯ）、ＩＧＦ－１Ｒ（１型インスリン様増殖因子）、ＧＤ２（ジシアロガングリオシド２）、ＴＭＩＧＤ２（膜貫通及び免疫グロブリンドメイン含有タンパク質２）、ＲＧＭＢ（ＲＧＭドメインファミリー、メンバーＢ）、ＶＩＳＴＡ（Ｔ細胞活性化のＶ－ドメイン免疫グロブリン含有抑制因子、Ｂ７－Ｈ５、Ｂ７ホモログ５）、ＢＴＮＬ２（ブチロフィリン様タンパク質２）、Ｂｔｎ（ブチロフィリンファミリー）、ＴＩＧＩＴ（Ｉｇ及びＩＴＩＭドメインを有するＴ細胞免疫受容体、Ｖｓｔｍ３、ＷＵＣＡＭ）、シグレック（シアル酸結合Ｉｇ様レクチン）、ニューロフィリン、ＶＥＧＦＲ（血管内皮増殖因子受容体）、ＩＬＴファミリー（ＬＩＲｓ、免疫グロブリン様転写物ファミリー、白血球免疫グロブリン様受容体）、ＮＫＧファミリー（ナチュラルキラー群ファミリー、Ｃ型レクチン膜貫通受容体）、ＭＩＣＡ（ＭＨＣクラスＩポリペプチド関連配列Ａ）、ＴＧＦβ（トランスフォーミング増殖因子β）、ＳＴＩＮＧ経路（インターフェロン遺伝子経路の刺激因子）、アルギナーゼ（アルギニンアミジナーゼ、カナバナーゼ、Ｌ－アルギナーゼ、アルギニントランスアミジナーゼ）、ＥＧＦＲｖＩＩＩ（上皮増殖因子受容体変異体ＩＩＩ）、ＨＨＬＡ２（Ｂ７－Ｈ７、Ｂ７ｙ、ＨＥＲＶ－Ｈ ＬＴＲ関連タンパク質２、Ｂ７ホモログ７）から選択される細胞標的に対する第２の抗体、ＰＤ－１（プログラム細胞死タンパク質１、ＰＤ－１、ＣＤ２７９、分化抗原群２７９）、ＰＤ－Ｌ１（Ｂ７－Ｈ１、Ｂ７ホモログ１、プログラム死リガンド１、ＣＤ２７４、分化抗原群２７４）、ＰＤ－Ｌ２（Ｂ７－ＤＣ、プログラム細胞死１リガンド２、ＰＤＣＤ１ＬＧ２、ＣＤ２７３、分化抗原群２７３）、ＣＴＬＡ－４（細胞傷害性Ｔリンパ球関連タンパク質４、ＣＤ１５２、分化抗原群１５２）、ＢＴＬＡ（Ｂ及びＴリンパ球アテニュエータ、ＣＤ２７２、分化抗原群２７２）、インドールアミン２，３－ジオキシゲナーゼ（ＩＤＯ、ＩＤＯ１）、ＴＩＭ３（ＨＡＶＣＲ２、Ａ型肝炎ウイルス細胞受容体２、Ｔ細胞免疫グロブリンムチン－３、ＫＩＭ－３、腎臓傷害分子３、ＴＩＭＤ－３、Ｔ細胞免疫グロブリンムチン－ドメイン３）、Ａ２Ａアデノシン受容体（ＡＤＯ受容体）、ＣＤ３９（エクトヌクレオシド三リン酸ジホスホヒドロラーゼ－１、分化抗原群３９、ＥＮＴＰＤ１）、ＣＤ７３（エクト－５’－ヌクレオチダーゼ、５’－ヌクレオチダーゼ、５’－ＮＴ、分化抗原群７３）、ＣＤ２７（分化抗原群２７）、ＩＣＯＳ（ＣＤ２７８、分化抗原群２７８、誘導性Ｔ細胞共刺激因子）、ＣＤ１３７（４－１ＢＢ、分化抗原群１３７、腫瘍壊死因子受容体スーパーファミリーメンバー９、ＴＮＦＲＳＦ９）、ＯＸ４０（ＣＤ１３４、分化抗原群１３４）、ＴＮＦＳＦ２５（腫瘍壊死因子受容体スーパーファミリーメンバー２５）、ＩＬ－１０（インターロイキン－１０、ヒトサイトカイン合成阻害因子、ＣＳＩＦ）、及びガレクチンの阻害剤からなる群から選択される細胞標的を対象とする、請求項１２に記載のモノクローナル抗体又はその抗原結合断片。 The therapeutic antibody is CD47 (differentiation antigen group 47), CD70 (differentiation antigen group 70), CD200 (OX-2 membrane glycoprotein, differentiation antigen group 200), CD154 (differentiation antigen group 154, CD40L, CD40 ligand, differentiation antigen group 40 ligand), CD223 (lymphocyte activation gene 3, LAG3, differentiation antigen group 223), KIR (killer cell immunoglobulin-like receptor), GITR (TNFRSF18, glucocorticoid-induced TNFR-related protein, activation-induced TNFR family receptor, AITR, tumor necrosis factor receptor superfamily member 18), CD20 (differentiation antigen group), CD28 (differentiation antigen group 28), CD40 (differentiation antigen group 40, Bp50, CDW40, TNFRSF5, tumor necrosis factor receptor somatic superfamily member 5, p50), CD86 (B7-2, differentiation antigen group 86), CD160 (differentiation antigen group 160, BY55, NK1, NK28), CD258 (LIGHT, differentiation antigen group 258, tumor necrosis factor ligand superfamily Member 14, TNFSF14, Herpes Virus Entry Mediator Ligand (HVEM-L), CD270 (HVEM, Tumor Necrosis Factor Receptor Superfamily Member 14, Herpes Virus Entry Mediator, Differentiation Group 270, LIGHTR, HVEA), CD275 (ICOSL, ICOS ligand, inducible T cell co-stimulatory factor ligand, differentiation antigen group 275), CD276 (B7-H3, B7 homolog 3, differentiation antigen group 276), OX40L (OX40 ligand), B7-H4 (B7 homolog 4, VTCN1, V Set domain containing T cell activation inhibitor 1), GITRL (glucocorticoid-inducible tumor necrosis factor receptor ligand, glucocorticoid-inducible TNFR ligand), 4-1BBL (4-1BB ligand), CD3 (differentiation antigen group 3, T3D ), CD25 (IL2Rα, differentiation antigen group 25, interleukin-2 receptor α chain, IL-2 receptor α chain), CD48 (differentiation antigen group 48, B lymphocyte activation marker, BLAST-1, signaling lymphocyte sphere-activating molecule 2, SLAMF2), CD66a (Ceacam-1, carcinoembryonic antigen-related cell adhesion molecule 1, bile glycoprotein, BGP, BGP1, BGPI, differentiation antigen group 66a), CD80 (B7-1, differentiation antigen group 80), CD94 (differentiation antigen group 94), NKG2A (natural killer group 2A, killer cell Chin-like receptor subfamily D member 1, KLRD1), CD96 (group of differentiation 96, TActILE, increased T-cell activation late expression), CD112 (PVRL2, nectin, poliovirus receptor-related 2, herpesvirus entry mediator B, HVEB, Nectin-2, differentiation antigen group 112), CD115 (CSF1R, colony-stimulating factor 1 receptor, macrophage colony-stimulating factor receptor, M-CSFR, differentiation antigen group 115), CD205 (DEC-205, LY75, lymphocyte antigen 75, differentiation antigen group 205), CD226 (DNAM1, differentiation antigen group 226, DNAX accessory molecule-1, PTA1, platelet and T cell activation antigen 1), CD244 (differentiation antigen group 244, natural killer cell receptor 2B4) , CD262 (DR5, TrailR2, TRAIL-R2, tumor necrosis factor receptor superfamily member 10b, TNFRSF10B, differentiation antigen group 262, KILLER, TRICK2, TRICKB, ZTNFR9, TRICK2A, TRICK2B), CD284 (Toll-like receptor-4, TLR4, differentiation antigen group 284), CD288 (Toll-like receptor-8, TLR8, differentiation antigen group 288), leukemia inhibitory factor (LIF), TNFSF15 (tumor necrosis factor superfamily member 15, vascular endothelial growth inhibitor, VEGI, TL1A ), TDO2 (tryptophan 2,3-dioxygenase, TPH2, TRPO), IGF-1R (type 1 insulin-like growth factor), GD2 (disialoganglioside 2), TMIGD2 (transmembrane and immunoglobulin domain-containing protein 2), RGMB (RGM domain family, member B), VISTA (V-domain immunoglobulin-containing suppressor of T cell activation, B7-H5, B7 homolog 5), BTNL2 (butyrophilin-like protein 2), Btn (butyrophilin family) , TIGIT (T cell immunoreceptor with Ig and ITIM domains, Vstm3, WUCAM), Siglec (sialic acid-binding Ig-like lectin) , neurophilin, VEGFR (vascular endothelial growth factor receptor), ILT family (LIRs, immunoglobulins like transcript family, leukocyte immunoglobulin-like receptor), NKG family (natural killer group family, C-type lectin transmembrane receptor), MICA (MHC class I polypeptide-related sequence A), TGFβ ( transforming growth factor beta), STING pathway (stimulator of the interferon gene pathway), arginase (arginine amidinase, canavanase, L-arginase, arginine transamidinase), EGFRvIII (epidermal growth factor receptor variant III) , A second antibody against a cellular target selected from H HLA2 (B7-H7, B7y, HERV-H LTR-associated protein 2, B7 homolog 7), PD-1 (programmed cell death protein 1, PD-1, CD279, differentiation antigen group 279), PD-L1 (B7-H1, B7 homolog 1, programmed death ligand 1, CD274, differentiation antigen group 274), PD-L2 (B7-DC, programmed cell death 1 ligand 2, PDCD1LG2, CD273, differentiation antigen group 273), CTLA-4 (cytotoxic T lymphocyte-associated protein 4, CD152, differentiation antigen group 152), BTLA (B and T lymphocyte attenuator, CD272, differentiation antigen group 272), indoleamine 2,3- dioxygenase (IDO, IDO1), TIM3 (HAVCR2, hepatitis A virus cell receptor 2, T-cell immunoglobulin mucin-3, KIM-3, kidney injury molecule 3, TIMD-3, T-cell immunoglobulin mucin-domain 3 ), A2A adenosine receptor (ADO receptor), CD39 (ectonucleoside triphosphate diphosphohydrolase-1, differentiation antigen group 39, ENTPD1) , CD73 (ecto-5′-nucleotidase, 5′-nucleotidase, 5′-NT, differentiation antigen group 73), CD27 (differentiation antigen group 27), ICOS (CD278, differentiation antigen group 278, inducible T cell co-stimulatory factor), CD137 (4-1BB, differentiation antigen group 137, tumor necrosis factor receptor superfamily member 9, TNFRSF9), OX40 (CD134, differentiation antigen group 134), TNFSF25 (tumor necrosis factor receptor superfamily member 25), IL-10 (interleukin-10, human cytokine synthesis inhibitor, CSIF ), and inhibitors of galectins . 前記モノクローナル抗体又はその抗原結合断片が、腫瘍細胞上の抗原を標的とするオプソニン化抗体と組み合わせて投与される、請求項１１に記載の癌治療用組成物。 12. The composition for treating cancer according to claim 11 , wherein said monoclonal antibody or antigen-binding fragment thereof is administered in combination with an opsonizing antibody that targets an antigen on tumor cells. 前記オプソニン化抗体が、リツキシマブ（抗ＣＤ２０）、トラスツズマブ（抗ＨＥＲ２）、アレムツズマブ（抗ＣＤ５２）、セツキシマブ（抗ＥＧＦＲ）、パニツムマブ（抗ＥＧＦＲ）、オファツムマブ（抗ＣＤ２０）、デノスマブ（抗ＲＡＮＫＬ）、ペルツズマブ（抗ＨＥＲ２）、パニツムマブ（抗ＥＧＦＲ）、ペルツズマブ（抗ＨＥＲ２）、エロツズマブ（抗ＳＬＡＭＦ７）、アテゾリズマブ（抗ＰＤ－Ｌ１）、アベルマブ（抗ＰＤ－Ｌ１）、デュルバルマブ（抗ＰＤ－Ｌ１）、ネシツムマブ（抗ＥＧＦＲ）、ダラツムマブ（抗ＣＤ３８）、オビヌツズマブ（抗ＣＤ２０）、ブリナツモマブ（抗ＣＤ１９／ＣＤ３）、及びジヌツキシマブ（抗ＧＤ２）からなる群から選択される、請求項１４に記載の癌治療用組成物。 The opsonizing antibody is rituximab (anti-CD20), trastuzumab (anti-HER2), alemtuzumab (anti-CD52), cetuximab (anti-EGFR), panitumumab (anti-EGFR), ofatumumab (anti-CD20), denosumab (anti-RANKL), pertuzumab (anti-HER2), panitumumab ( anti- EGFR), pertuzumab ( anti- HER2), elotuzumab ( anti- SLAMF7), atezolizumab (anti-PD-L1), avelumab (anti-PD-L1), durvalumab (anti-PD-L1), necitumumab (anti-PD-L1) EGFR), daratumumab (anti-CD38), obinutuzumab (anti-CD20), blinatumomab (anti-CD19/CD3), and dinutuximab (anti-GD2). 腫瘍細胞上の標的抗原が、ＣＤ２０、ＥＧＦＲ、及びＰＤ－Ｌ１からなる群から選択される、請求項１４に記載の癌治療用組成物。 15. The composition for treating cancer according to claim 14 , wherein the target antigen on tumor cells is selected from the group consisting of CD20, EGFR, and PD-L1. 前記癌が、白血病、リンパ腫、多発性骨髄腫、卵巣癌、乳癌、子宮内膜癌、結腸癌、直腸癌、膀胱癌、尿路上皮癌、肺癌、気管支癌、骨癌、前立腺癌、膵臓癌、胃癌、肝細胞癌、膀胱癌、胆管癌、食道癌、腎細胞癌、甲状腺癌、頭部及び頚部の扁平上皮癌、精巣癌、内分泌腺癌、副腎腺癌、脳下垂体癌、皮膚癌、軟組織の癌、血管の癌、脳腫瘍、神経癌、眼の癌、髄膜癌、中咽頭癌、下咽頭癌、子宮頸癌、子宮癌、膠芽腫、髄芽腫、星細胞腫、神経膠腫、髄膜腫、ガストリノーマ、神経芽細胞腫、黒色腫、骨髄異形成症候群、並びに肉腫からなる群から選択される、請求項１１に記載の癌治療用組成物。 The cancer is leukemia, lymphoma, multiple myeloma, ovarian cancer, breast cancer, endometrial cancer, colon cancer, rectal cancer, bladder cancer, urothelial cancer, lung cancer, bronchial cancer, bone cancer, prostate cancer, pancreas Cancer, gastric cancer, hepatocellular carcinoma, bladder cancer, cholangiocarcinoma, esophageal cancer, renal cell carcinoma, thyroid cancer, head and neck squamous cell carcinoma, testicular cancer, endocrine adenocarcinoma, adrenal adenocarcinoma, pituitary carcinoma, skin Cancer, soft tissue cancer, vascular cancer, brain tumor, nerve cancer, eye cancer, meningeal cancer, oropharyngeal cancer, hypopharyngeal cancer, cervical cancer , uterine cancer, glioblastoma, medulloblastoma, astrocytoma , glioma, meningioma , gastrinoma , neuroblastoma, melanoma, myelodysplastic syndrome, and sarcoma . 前記白血病が、全身性肥満細胞症、急性リンパ性（リンパ芽球性）白血病（ＡＬＬ）、Ｔ細胞ＡＬＬ、急性骨髄性白血病（ＡＭＬ）、慢性リンパ性白血病（ＣＬＬ）、慢性骨髄性白血病（ＣＭＬ）、骨髄増殖性疾患／腫瘍、骨髄異形成症候群、単球性白血病、及びプラズマ細胞白血病病からなる群から選択される；
前記リンパ腫が、組織球性リンパ腫、Ｔ細胞リンパ腫、Ｂ細胞リンパ腫、低悪性度／濾胞性非ホジキンリンパ腫（ＮＨＬ）、細胞リンパ腫（ＦＣＣ）、マントル細胞リンパ腫（ＭＣＬ）、びまん性大細胞リンパ腫（ＤＬＣＬ）、小リンパ球性（ＳＬ）ＮＨＬ、中悪性度／濾胞性ＮＨＬ、中悪性度びまん性ＮＨＬ、高悪性度免疫芽球性ＮＨＬ、高悪性度リンパ球性ＮＨＬ、高悪性度小型非切れ込み核細胞性ＮＨＬ、巨大病変（ｂｕｌｋｙ ｄｉｓｅａｓ）ＮＨＬ、及びワルデンシュトレーム型マクログロブリン血症（Ｗａｌｄｅｎｓｔｒｏｍ’ｓ Ｍａｃｒｏｇｌｏｂｕｌｉｎｅｍｉａ）からなる群から選択される；
前記肺癌が、非小細胞肺癌、肺の腺癌、及び肺の扁平上皮癌からなる群から選択される；及び
前記肉腫が、骨肉腫、ユーイング肉腫、平滑筋肉腫、滑膜肉腫、胞巣状軟部肉腫、血管肉腫、脂肪肉腫、線維肉腫、横紋筋肉腫、及び軟骨肉腫からなる群から選択される、請求項１１に記載の癌治療用組成物。 said leukemia is systemic mastocytosis, acute lymphocytic (lymphoblastic) leukemia (ALL), T-cell ALL, acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML) ), myeloproliferative disease/tumor, myelodysplastic syndrome, monocytic leukemia, and plasma cell leukemia;
The lymphoma is histiocytic lymphoma, T-cell lymphoma, B-cell lymphoma, low-grade/follicular non-Hodgkin's lymphoma (NHL), cellular lymphoma (FCC), mantle cell lymphoma (MCL), diffuse large cell lymphoma (DLCL) ), small lymphocytic (SL) NHL, intermediate/follicular NHL, intermediate-grade diffuse NHL, high-grade immunoblastic NHL, high-grade lymphocytic NHL, high-grade small non-cleaved nuclei selected from the group consisting of cellular NHL, bulky diseases NHL, and Waldenstrom's Macroglobulinemia;
said lung cancer is selected from the group consisting of non-small cell lung cancer, adenocarcinoma of the lung, and squamous cell carcinoma of the lung; and
The sarcoma is selected from the group consisting of osteosarcoma, Ewing's sarcoma, leiomyosarcoma, synovial sarcoma, alveolar soft part sarcoma, angiosarcoma, liposarcoma, fibrosarcoma, rhabdomyosarcoma, and chondrosarcoma. Item 12. The composition for cancer treatment according to Item 11 .
JP2021525789A 2018-11-14 2019-11-13 Therapeutic SIRPα antibody Withdrawn JP2022507295A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862767509P 2018-11-14 2018-11-14
US62/767,509 2018-11-14
US201962820718P 2019-03-19 2019-03-19
US62/820,718 2019-03-19
US201962886872P 2019-08-14 2019-08-14
US62/886,872 2019-08-14
US201962931746P 2019-11-06 2019-11-06
US62/931,746 2019-11-06
PCT/US2019/061278 WO2020102422A1 (en) 2018-11-14 2019-11-13 THERAPEUTIC SIRPα ANTIBODIES

Publications (2)

Publication Number Publication Date
JP2022507295A JP2022507295A (en) 2022-01-18
JPWO2020102422A5 true JPWO2020102422A5 (en) 2022-11-21

Family

ID=70730617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021525789A Withdrawn JP2022507295A (en) 2018-11-14 2019-11-13 Therapeutic SIRPα antibody

Country Status (8)

Country Link
US (2) US11202828B2 (en)
EP (1) EP3880239A4 (en)
JP (1) JP2022507295A (en)
CN (1) CN113573728A (en)
AU (1) AU2019380503A1 (en)
BR (1) BR112021009325A2 (en)
CA (1) CA3119748A1 (en)
WO (1) WO2020102422A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190009A1 (en) 2016-09-21 2019-01-27 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use
MX2020009774A (en) 2018-03-21 2020-10-08 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use.
CN112574310B (en) * 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 anti-SIRP alpha antibodies and uses thereof
US20240101716A1 (en) * 2020-12-18 2024-03-28 La Nova Medicines Development Co., Ltd. BISPECIFIC ANTIBODIES TARGETING SIRPa AND PD-L1
CN117355539A (en) * 2021-05-28 2024-01-05 百奥泰生物制药股份有限公司 anti-SIRP alpha antibody and application thereof
EP4347653A1 (en) 2021-06-04 2024-04-10 Boehringer Ingelheim International GmbH Anti-sirp-alpha antibodies
CN113956363B (en) 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 Recombinant fusion protein targeting CD47 and CD24 and preparation and application thereof
CN117447594A (en) * 2022-07-26 2024-01-26 北京东方百泰生物科技股份有限公司 anti-Siglec-15 monoclonal antibody
CN115819586B (en) * 2022-10-13 2023-10-31 珠海市丽珠单抗生物技术有限公司 Anti-human SIRP alpha monoclonal antibody and application thereof
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2592672C9 (en) * 2010-12-08 2016-11-27 СтемСентРкс, Инк. Novel modulators and methods for use thereof
CN103857696B (en) * 2011-08-17 2017-07-04 加利福尼亚大学董事会 With reference to the antibody of integin αV β 8
EP2780371B1 (en) * 2011-11-16 2018-10-24 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
ES2698606T3 (en) 2012-01-20 2019-02-05 Genzyme Corp Anti-CXCR3 antibodies
CA3020373A1 (en) * 2016-04-14 2017-10-19 Ose Immunotherapeutics New anti-sirpa antibodies and their therapeutic applications
JOP20190009A1 (en) * 2016-09-21 2019-01-27 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
JP7160833B2 (en) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． anti-SIRP alpha antibody

Similar Documents

Publication Publication Date Title
JP6955507B2 (en) Bispecificity with immune responsiveness to PD-1 and CTLA-4 and how to use it
TWI773646B (en) Lag-3-binding molecules and methods of use thereof
US11167029B2 (en) Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy
JP7404423B2 (en) Humanized anti-human PD-1 antibody
US11202828B2 (en) Therapeutic SIRP-α antibodies
US20220025050A1 (en) Bifunctional molecule directed against human pd-1
JP2019500892A5 (en)
JP2020514363A5 (en)
KR20180093127A (en) PD-1-Binding Molecules and Methods of Use Thereof
RU2018126297A (en) ANTIBODIES AIMED AT CD32B AND WAYS TO USE THEM
JP7480307B2 (en) Means and methods for modulating immune cell-mediated effects
JP2021524451A (en) Optimized gp41 binding molecule and its use
JPWO2020102422A5 (en)
US20230279108A1 (en) Therapeutic sirp-alpha antibodies
EP3091031A1 (en) Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
JP7378567B2 (en) LAG-3 binding molecules and methods of use thereof
US20240182572A1 (en) Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
JPWO2021183207A5 (en)